Why the study?
Does isradipine affect electrocardiographic ischemia in patients with hypertension?
Does isradipine affect electrocardiographic ischemia in patients with hypertension?
Treatment with isradipine for blood pressure control in hypertensive patients does not significantly increase the incidence of electrocardiographic ischemia.
Answers are grounded in this paper and cite their sources.
Isradipine does not increase electrocardiographic ischemia in hypertension; confirms safety for blood pressure control without added ischemic risk.
A total of 203 patients with hypertension (supine diastolic blood pressure of 100–119 mm Hg) from six centers entered into a 3‐week placebo baseline followed by 5 weeks of active treatment (either placebo or isradipine 2.5, 5, 7.5, or 10 mg BID) to determine the effectiveness of isradipine on blood pressure control. Electrocardiographic criteria for left‐ventricular ischemia were coded blindly using the Minnesota Codes 4‐1 to 4‐4 and 5‐1 to 5‐3 at the end of baseline and active treatment periods. One hundred seventy patients with hypertension and matching and complete electrocardiograms completed the study for analysis: 63 (37%) were white and 117 (69%) were men. They were 52.1 ± 10.3 years old mean ± SD; range: 22–77 years). No myocardial infarction occurred during the active phase. Fifty‐eight of 170 (34%) at baseline and 54 of 116 (32%) at week 5 had left atrial enlargement. Romhilt‐Estes left‐ventricular hypertrophy was not significantly different at baseline versus active treatment: 14 of 170 (8.2%) versus 15 of 170 (8.8%). At baseline, the rate of active ischemia was 28.2% (48/170); 27.8% (10/36) were randomized to receive placebo during active treatment and 28.4% (38/134) were given isradipine (P = NS). For those without ischemia at baseline, the rate of change to electrocardiographic ischemia during active treatment was 0% (0/26) for those receiving placebo and 3.1% (3/96) for those taking isradipine (P = NS). For those with ischemia at baseline, the rate of change to no ischemia during active treatment was 20% (2/10) for those receiving placebo and 10.5% (4/38) for those taking isradipine (P = NS). Overall, ischemia at baseline versus active treatment was: placebo (P = NS)‐27.8% (10/36) to 22.2% (8/36); and isradipine (P = NS)‐28.4% (38/134) to 27.6% (37/134). However, 3 of 96 patients without ischemia at baseline changed to ischemia while receiving isradipine. Such individuals should be investigated for epicardial coronary artery disease. In contrast, 4 of 38 patients with ischemia at baseline reverted to no ischemia while taking isradipine. The group that received isradipine and had good diastolic blood pressure control did not have more electrocardiographic ischemia.
No takes yet. Share an insight, caveat, or question.
Prisant et al. (1991) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: